Context Therapeutics, Inc. (CNTX)

Context Therapeutics's stock has experienced a share price decline, analyst coverage with 'Buy' or 'Overweight' recommendations, and company announcements including presentations and financial results. The share price declined by 34.55% between November 19, 2024, and November 18, 2025, and the 52-week low was $0.49 on May 30, 2025. Analyst coverage has been active, with a consensus of 'Moderate Buy' and a predicted upside of 377.88%. Company announcements include highlighting CT-95 and CT-202 programs, reporting Third Quarter 2025 results, participation in investor conferences, poster presentations, and an inducement grant.

Traditional demand seasonality does not directly apply to Context Therapeutics's current business model as a clinical-stage biopharmaceutical company focused on drug candidate development rather than commercialized products. Seasonal patterns for its stock price may exist, but this is distinct from product demand seasonality.

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumor treatment, operating within the Healthcare sector and Biotechnology industry. The company is advancing a portfolio of TCE bispecific therapeutics, including lead program candidate CTIM-76, CT-95, and CT-202. They also have a collaboration and licensing agreement with Integral Molecular, Inc.

Context Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States.

Context Therapeutics's brand reputation appears moderately positive, with a news sentiment score of 0.58. News coverage has been slightly above average, while search interest and watchlist additions have been low. Analysts have a 'Moderate Buy' consensus rating. The company scored higher than 71% of companies evaluated by MarketBeat, ranking 217th out of 941 stocks in the medical sector.

Context Therapeutics has a mixed ownership structure including institutional shareholders, insiders, and retail investors. Institutional shareholders hold a significant portion, ranging from 14.03% to 83.34%. Major institutional owners include MPM Bioimpact LLC, Avidity Partners Management LP, and others. Insiders own approximately 1.35% to 1.43% of the company's stock, with Martin A. Lehr being the largest individual shareholder. Retail investors hold between 23.51% and 25.21% of the shares.